Human endogenous retroviruses in cancer: Oncogenesis mechanisms and clinical implications. Issue 1 (7th December 2022)

• Record Type: Journal Article
• Authors: Kitsou, Konstantina; Lagiou, Pagona; Magiorkinis, Gkikas
• Is Part Of: Journal of medical virology. Volume 95:Issue 1(2023)
• Page Start: n/a
• Page End: n/a
• Publication Date: 2022-12-07
• Subjects: cancer -- evolution -- HERVs in oncogenesis -- HERV‐K (HML‐2) -- human endogenous retrovirus; Virology -- Periodicals; 616
• DOI: 10.1002/jmv.28350
• Languages: English
• ISSNs: 0146-6615

Abstract

Abstract: Human Endogenous Retroviruses (HERVs) are viral sequences integrated into the human genome, resulting from the infection of human germ‐line cells by ancient exogenous retroviruses. Despite losing their replication and retrotransposition abilities, HERVs appear to have been co‐opted in human physiological functions while their aberrant expression is linked to human disease. The role of HERVs in multiple malignancies has been demonstrated, however, the extent to which HERV activation and expression participate in the development of cancer is not yet fully comprehended. In this review article, we discuss the presumed role of HERVs in carcinogenesis and their promising diagnostic and prognostic implications. Additionally, we explore recent data on the HERVs in cancer therapeutics, either through the manipulation of their expression, to induce antitumor innate immunity responses or as cancer immunotherapy targets. Finally, more precise and higher resolution high‐throughput sequencing approaches will further elucidate HERV participation in human physiological and pathological processes.